Adding Value: Sanofi, Google Partner On Diabetes Management
This article was originally published in Scrip
Sanofi and Google's unnamed life science company entered into a partnership to help diabetes patients and their doctors monitor their disease and remain compliant with dosing schedules for glucose-lowering medications via technology that has yet to be defined, but will amount to more than yet another easily ignored smartphone application.
You may also be interested in...
Olema launched this year’s 76th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.
The $80m financing will support a Phase III myelofibrosis study for the LSD1 inhibitor and earlier-stage programs, but additional late-stage studies will require an initial public offering, likely next year.
Public Company Edition: Three companies postponed or withdrew their offerings, but drug developers continue to pursue IPOs. Also, Biocon, BMS and Epizyme raised money through new debt, Five Prime capitalized on positive data and Synthetic Biologic engaged a strategic advisor.